Saturday 17 October 2026
Export INBX’s income statement to Excel — free account
Inhibrx Biosciences, Inc.
INBX Healthcare Biotechnology
Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024. In the quarter to June 2026, revenue grew 992.4%, EPS fell 26.5%, free cash flow was flat and total debt rose 77.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
89.83
0.67
−0.74%
Follow INBX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 10.80 | 10.81 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 18.95 | 94.57 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 163 | 161 | 110 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.01 | 0.00 | 0.01 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 2 | 0 | 1 | ||||
| Gross margin, % | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | — | — | (115) | (240) | 1,688 | (140) | |||||
| EBT margin, % | — | — | — | — | — | — | (8,769.73) | (13,318.00) | 843,787.00 | (10,773.31) | |||||
| Net income | — | — | — | — | — | — | (115) | (241) | 1,688 | (140) | |||||
| Depreciation | — | — | — | — | — | — | 1 | 1 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.15 | 0.01 | 0.08 | ||||
| Earnings | — | — | — | — | — | — | — | (20.48) | 114.01 | (9.04) | |||||
| Cash flow | — | — | — | — | — | — | 0.00 | (16.41) | (13.13) | (8.38) | |||||
| Capex | — | — | — | — | — | — | 0.00 | (0.39) | (0.18) | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | 0.00 | (16.80) | (13.31) | (8.38) | |||||
| Book value | — | — | — | — | — | — | 0.00 | 3.69 | 9.02 | 0.52 | |||||
| Shares, m | — | — | — | — | — | — | — | 12 | 15 | 15 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.13 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | 0.00 | 115.71 | 388.28 | |||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 1.71 | 153.07 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 143.31 | 380.77 | |||||
| EV/FCF | — | — | — | — | — | — | (0.58) | (0.58) | (1.43) | (9.24) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (91) | (193) | (194) | (130) | ||||
| Capex | — | — | — | — | — | — | (1) | (5) | (3) | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (91) | (198) | (197) | (130) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (15) | 239 | 120 | 99 | ||||
| Total debt | — | — | — | — | — | — | — | 207 | — | 101 | |||||
| Net debt | — | — | — | — | — | — | — | (71) | (153) | (24) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (7) | 44 | 134 | 8 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (148.74) | 690.69 | (85.60) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | (1,333.38) | 1,905.92 | (197.85) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2025
Charts ten years each
Inhibrx Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RAPP Rapport Therapeutics, Inc. | $1.4B | — (loss-making) | — | — | n/m | −64.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | Compare |
| OMER Omeros Corporation | $1.4B | 9.5× | 2.1× | +35.46% (above 0%: growing) | n/m | +118.70% (above 0%: growing) | 97.20% | 0.26% | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.3B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | |
| ORIC Oric Pharmaceuticals, Inc. | $1.3B | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TYRA Tyra Biosciences, Inc. | $1.3B | — (loss-making) | — | — | n/m | −31.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GHRS GH Research PLC | $1.3B | — (loss-making) | — | — | n/m | −66.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NKTR Nektar Therapeutics | $1.3B | — (loss-making) | — (loss-making) | −9.34% (below 0%: shrinking) | n/m | −65.73% (below 0%: shrinking) | 100.00% | (417.94%) | Compare |
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $1.3B | — | — | — | — | −30.88% | 0.00% | 0.00% |
Inhibrx Biosciences, Inc. (INBX) key facts
- Strength: Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024.
- Inhibrx Biosciences, Inc. (INBX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, INBX traded at $89.83, a market capitalization of $1.3 billion.
- Return on equity was −197.9% and debt-to-equity -3.33.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.73 (distress zone) for fiscal 2025.